X

Trial Profile

A study of CAP-003

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAP 003 (Primary)
Indications Parkinson's disease
Focus Adverse reactions

Most Recent Events

04 Sep 2024 According to Capsida Biotherapeutics media release, the company will participate in upcoming conferences and highlight the progress with wholly owned IV-administered programs CAP-002 in genetic epilepsy due to STXBP1 mutations and CAP-003 in Parkinson's disease associated with GBA mutations. Both programs are on track to enter the clinic in the first half of 2025.
14 May 2024 New trial record
10 May 2024 According to a Capsida Biotherapeutics media release, company plans to advance the therapy into clinical trials in the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com